trending Market Intelligence /marketintelligence/en/news-insights/trending/EG6oOLZlb_6EXg__1xeYug2 content esgSubNav
In This List

HVIVO director resigns

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


HVIVO director resigns

HVIVO PLC said Graham Yeatman stopped being a director of the company, effective Dec. 31, 2018.

As previously announced in September 2018, Yeatman also stepped down as hVIVO's chief financial and business officer.

He joined the company's board as finance director in 2011 and was promoted to the chief financial and business officer post in 2015.

The company has named Shelley Fraser to replace Yeatman as finance director.

London-based hVIVO is developing a human-based clinical trial platform for drug and vaccine development in respiratory and infectious diseases.